This update develops the actual therapeutic options in the management of the joint involvement of calcium pyrophosphate deposition disease (CPPD), basic calcium phosphate (BCP) deposition disease, hemochromatosis (HH), ochronosis, oxalosis, and Wilson’s disease. Conventional pharmaceutical treatment provides benefits for most diseases. Anti-interleukine-1 (IL-1) treatment could provide similar results in CPPD than in gout flares. There is only limited evidence about the efficacy of preventive long-term colchicine intake, methotrexate, and hydroxychloroquine in chronic CPPD. Needle aspiration and lavage have satisfactory short and midterm results in BCP. Extracorporeal shockwave therapy has also proved its efficacy for high-doses regimes. Phlebotomy does not seem to have shown real efficacy on joint involvement in HH so far. Iron chelators’ effects have not been assessed on joint involvement either, while IL-1 blockade may prove useful. NSAIDs have limited efficacy on joint involvement of oxalosis, while colchicine and steroids have not been assessed either. The use of nitisinone for ochronotic arthropathy is still much debated, but it could provide beneficial effects on joint involvement. The effects of copper chelators have not been assessed either in the joint involvement of Wilson’s disease. NSAIDs should be avoided because of the liver affection they may worsen. 1. Introduction New interest in crystal-induced arthropathies has developed over the last few years mainly through the new discoveries on gout pathophysiology and especially with the understanding of the inflammasome [1] which paved the way for new therapeutic options [2]. These breakthroughs in the field of gout have given a new insight into other crystal-induced arthropathies [3] and recent international guidelines have been produced for both the treatment of gout [4, 5] and calcium pyrophosphate deposition (CPPD) [6]. However, other crystal-induced rheumatisms such as the basic calcium phosphate (BCP) deposition disease [7] do not seem to have benefited from these new developments although they are widespread in clinical practice. Rare conditions such as hemochromatosic arthropathy [8], ochronotic arthropathy [9], Wilson’s disease [10], and oxalate crystal deposition disease [11] can lead to difficult clinical situations. Other joint deposition-related entities such as cholesterol crystal arthropathy, cryoglobulin-crystal arthropathy, liquid lipid crystals arthropathy, corticosteroid crystals-induced arthritis, or Charcot-Leyden crystals deposition are exceptional and therefore not
References
[1]
F. Martinon, V. Pétrilli, A. Mayor, A. Tardivel, and J. Tschopp, “Gout-associated uric acid crystals activate the NALP3 inflammasome,” Nature, vol. 440, no. 7081, pp. 237–241, 2006.
[2]
C. M. Burns and R. L. Wortmann, “Gout therapeutics: new drugs for an old disease,” The Lancet, vol. 377, no. 9760, pp. 165–177, 2011.
[3]
S. Ottaviani, L. Brunier, J. Sibilia, F. Maurier, M. Ardizzone, D. Wendling, et al., “Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: a report of 16 cases and review of the literature,” Joint Bone Spine, vol. 80, no. 2, pp. 178–182, 2013.
[4]
D. Khanna, J. D. Fitzgerald, P. P. Khanna, S. Bae, M. K. Singh, T. Neogi, et al., “2012 American College of Rheumatology guidelines for management of gout—part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia,” Arthritis Care & Research, vol. 64, no. 10, pp. 1431–1446, 2012.
[5]
D. Khanna, P. P. Khanna, J. D. Fitzgerald, M. K. Singh, S. Bae, T. Neogi, et al., “2012 American College of Rheumatology guidelines for management of gout—part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis,” Arthritis Care & Research, vol. 64, no. 10, pp. 1447–1461, 2012.
[6]
W. Zhang, M. Doherty, E. Pascual et al., “EULAR recommendations for calcium pyrophosphate deposition—part II: management,” Annals of the Rheumatic Diseases, vol. 70, no. 4, pp. 571–575, 2011.
[7]
B. Bosworth, “Calcium deposits in the shoulder and subacromial bursitis: a survey of 12, 122 shoulders,” The Journal of the American Medical Association, vol. 116, no. 22, pp. 2477–2482, 1941.
[8]
G. J. Carroll, W. H. Breidahl, and J. K. Olynyk, “Characteristics of the arthropathy described in hereditary hemochromatosis,” Arthritis Care & Research, vol. 64, no. 1, pp. 9–14, 2012.
[9]
C. Phornphutkul, W. J. Introne, M. B. Perry et al., “Natural history of alkaptonuria,” The New England Journal of Medicine, vol. 347, no. 26, pp. 2111–2121, 2002.
[10]
A.-S. Quemeneur, J.-M. Trocello, H.-K. Ea, F. Woimant, and F. Lioté, “Miscellaneous non-inflammatory musculoskeletal conditions. Musculoskeletal conditions associated with Wilson’s disease,” Best Practice & Research Clinical Rheumatology, vol. 25, no. 5, pp. 627–636, 2011.
[11]
I. Maldonado, V. Prasad, and A. J. Reginato, “Oxalate crystal deposition disease,” Current Rheumatology Reports, vol. 4, no. 3, pp. 257–264, 2002.
[12]
G. P. Rodnan, “Treatment of the gout and other forms of crystal-induced arthritis,” Bulletin on the Rheumatic Diseases, vol. 32, no. 5, pp. 43–53, 1982.
[13]
M. Doherty, “Calcium pyrophosphate deposition disease and other crystal deposition diseases,” Current Opinion in Rheumatology, vol. 2, no. 5, pp. 789–796, 1990.
[14]
P. Richette, T. Bardin, and M. Doherty, “An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition disease,” Rheumatology, vol. 48, no. 7, pp. 711–715, 2009.
[15]
D. Daoussis, I. Antonopoulos, G. Yiannopoulos, and A. P. Andonopoulos, “ACTH as first line treatment for acute calcium pyrophosphate crystal arthritis in 14 hospitalized patients,” Joint Bone Spine, vol. 81, no. 1, pp. 98–100, 2014.
[16]
S. Ottaviani, L. Brunier, J. Sibilia, F. Maurier, M. Ardizzone, D. Wendling, et al., “Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: a report of 16 cases and review of the literature,” Joint Bone Spine, vol. 80, no. 2, pp. 178–182, 2013.
[17]
S. Ottaviani, A. Moltó, H.-K. Ea, S. Neveu, G. Gill, L. Brunier, et al., “Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases,” Arthritis Research & Therapy, vol. 15, no. 5, article R123, 2013.
[18]
N. Announ and P.-A. Guerne, “Treating difficult crystal pyrophosphate dihydrate deposition disease,” Current Rheumatology Reports, vol. 10, no. 3, pp. 228–234, 2008.
[19]
A. Alvarellos and I. Spilberg, “Colchicine prophylaxis in pseudogout,” Journal of Rheumatology, vol. 13, no. 4, pp. 804–805, 1986.
[20]
S. K. Das, K. Mishra, S. Ramakrishnan et al., “A randomized controlled trial to evaluate the slow-acting symptom modifying effects of a regimen containing colchicine in a subset of patients with osteoarthritis of the knee,” Osteoarthritis and Cartilage, vol. 10, no. 4, pp. 247–252, 2002.
[21]
A. Chollet-Janin, A. Finckh, J. Dudler, and P.-A. Guerne, “Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis,” Arthritis & Rheumatism, vol. 56, no. 2, pp. 688–692, 2007.
[22]
B. Rothschild and L. E. Yakubov, “Prospective 6-month, double-blind trial of hydroxychloroquine treatment of CPDD,” Comprehensive Therapy, vol. 23, no. 5, pp. 327–331, 1997.
[23]
T. H. T. Doan, X. Chevalier, J. M. Leparc, P. Richette, T. Bardin, and R. Forestier, “Premature enthusiasm for the use of methotrexate for refractory chondrocalcinosis: comment on the article by Chollet-Janin et al,” Arthritis & Rheumatism, vol. 58, no. 7, pp. 2210–2211, 2008.
[24]
M. Andres, F. Sivera, and E. Pascual, “Methotrexate is an option for patients with refractory calcium pyrophosphate crystal arthritis,” Journal of Clinical Rheumatology, vol. 18, no. 5, pp. 234–236, 2012.
[25]
G. D. Wright and M. Doherty, “Calcium pyrophosphate crystal deposition is not always “wear and tear” or aging,” Annals of the Rheumatic Diseases, vol. 56, no. 10, pp. 586–588, 1997.
[26]
M. Doherty and P. A. Dieppe, “Double blind, placebo controlled trial of magnesium carbonate in chronic pyrophosphate arthropathy,” Annals of the Rheumatic Diseases, vol. 42, pp. 106–107, 1983.
[27]
F. Verhoeven, C. Prati, M. Godfrin-Valnet, X. Guillot, and D. Wendling, “IL1 blockade in crystal-induced arthritis: impact of disease duration and the inflammatory syndrome. Comments on the article by Couderc M. et al. ‘Efficacy of anakinra in articular chondrocalcinosis’,” Joint Bone Spine, vol. 80, no. 1, pp. 115–116, 2013.
[28]
M. Couderc, S. Mathieu, B. Glace, and M. Soubrier, “Efficacy of anakinra in articular chondrocalcinosis: report of three cases,” Joint Bone Spine, vol. 79, no. 3, pp. 330–331, 2012.
[29]
V. Srinivasan, A. Wensel, P. Dutcher, S. Newlands, M. Johnson, and G. E. Vates, “Calcium pyrophosphate deposition disease of the temporomandibular joint,” Journal of Neurological Surgery Reports, vol. 73, no. 1, pp. 6–8, 2012.
[30]
M. H. Wener, “Destructive temporomandibular joint disease: also consider tophaceous voracious (hydroxy)apatite,” The Journal of Rheumatology, vol. 36, no. 2, pp. 453–454, 2009.
[31]
D. J. McCarty, P. B. Halverson, and G. F. Carrera, “‘Milwaukee shoulder’—association of microspheroids containing hydroxyapatite crystals, active collagenase, and neutral protease with rotator cuff defects. I. Clinical aspects,” Arthritis & Rheumatism, vol. 24, no. 3, pp. 464–473, 1981.
[32]
C. R. Carcia and J. S. Scibek, “Causation and management of calcific tendonitis and periarthritis,” Current Opinion in Rheumatology, vol. 25, no. 2, pp. 204–209, 2013.
[33]
G. Serafini, L. M. Sconfienza, F. Lacelli, E. Silvestri, A. Aliprandi, and F. Sardanelli, “Rotator cuff calcific tendonitis: short-term and 10-year outcomes after two-needle US-guided percutaneous treatment—nonrandomized controlled trial1,” Radiology, vol. 252, no. 1, pp. 157–164, 2009.
[34]
P. B. de Witte, J. W. Selten, A. Navas et al., “Calcific tendinitis of the rotator cuff: a randomized controlled trial of ultrasound-guided needling and lavage versus subacromial corticosteroids,” The American Journal of Sports Medicine, vol. 41, pp. 1665–1673, 2013.
[35]
L. Gerdesmeyer, S. Wagenpfeil, M. Haake et al., “Extracorporeal shock wave therapy for the treatment of chronic calcifying tendonitis of the rotator cuff: a randomized controlled trial,” Journal of the American Medical Association, vol. 290, no. 19, pp. 2573–2580, 2003.
[36]
C. Speed, “A systematic review of shockwave therapies in soft tissue conditions: focusing on the evidence,” British Journal of Sports Medicine, 2013.
[37]
F. Ioppolo, M. Tattoli, L. di Sante et al., “Clinical improvement and resorption of calcifications in calcific tendinitis of the shoulder after shock wave therapy at 6 months’ follow-up: a systematic review and meta-analysis,” Archives of Physical Medicine and Rehabilitation, vol. 94, no. 9, pp. 1699–1706, 2013.
[38]
G. R. Ebenbichler, C. B. Erdogmus, K. L. Resch et al., “Ultrasound therapy for calcific tendinitis of the shoulder,” The New England Journal of Medicine, vol. 340, no. 20, pp. 1533–1538, 1999.
[39]
P. Zufferey and A. So, “A pilot study of IL-1 inhibition in acute calcific periarthritis of the shoulder,” Annals of the Rheumatic Diseases, vol. 72, no. 3, pp. 465–467, 2013.
[40]
M. Balke, R. Bielefeld, C. Schmidt, N. Dedy, and D. Liem, “Calcifying tendinitis of the shoulder: midterm results after arthroscopic treatment,” The American Journal of Sports Medicine, vol. 40, no. 3, pp. 657–661, 2012.
[41]
O. Epis, R. Caporali, C. A. Scirè, E. Bruschi, E. Bonacci, and C. Montecucco, “Efficacy of tidal irrigation in Milwaukee shoulder syndrome,” The Journal of Rheumatology, vol. 34, no. 7, pp. 1545–1550, 2007.
[42]
P. Ornetti, N. Vernier, and C. Fortunet, “Milwaukee shoulder syndrome affecting the elbow,” Arthritis & Rheumatism, vol. 65, no. 2, p. 538, 2013.
[43]
K. J. Allen, L. C. Gurrin, C. C. Constantine et al., “Iron-overload-related disease in HFE hereditary hemochromatosis,” The New England Journal of Medicine, vol. 358, no. 3, pp. 221–230, 2008.
[44]
P. Richette, S. Ottaviani, E. Vicaut, and T. Bardin, “Musculoskeletal complications of hereditary hemochromatosis: a case-control study,” The Journal of Rheumatology, vol. 37, no. 10, pp. 2145–2150, 2010.
[45]
E. Sahinbegovic, T. Dallos, E. Aigner et al., “Musculoskeletal disease burden of hereditary hemochromatosis,” Arthritis & Rheumatism, vol. 62, no. 12, pp. 3792–3798, 2010.
[46]
P. Richette, C. Eymard, M. Deberg et al., “Increase in type II collagen turnover after iron depletion in patients with hereditary haemochromatosis,” Rheumatology, vol. 49, no. 4, pp. 760–766, 2010.
[47]
P. Phatak, P. Brissot, M. Wurster et al., “A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis,” Hepatology, vol. 52, no. 5, pp. 1671–1779, 2010.
[48]
G. J. Kontoghiorghes, “A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?” Expert Opinion on Drug Safety, vol. 12, no. 5, pp. 605–609, 2013.
[49]
A. Latourte, A. Frazier, C. Brière, H.-K. Ea, and P. Richette, “Interleukin-1 receptor antagonist in refractory haemochromatosis-related arthritis of the hands,” Annals of the Rheumatic Diseases, vol. 72, no. 5, pp. 783–784, 2013.
[50]
M. Elmberg, R. Hultcrantz, J. F. Simard, A. Carlsson, and J. Askling, “Increased risk of arthropathies and joint replacement surgery in patients with genetic hemochromatosis,” Arthritis Care & Research, vol. 65, no. 5, pp. 678–685, 2013.
[51]
S. El Hage, I. Ghanem, A. Baradhi et al., “Skeletal features of primary hyperoxaluria type 1, revisited,” Journal of Children's Orthopaedics, vol. 2, no. 3, pp. 205–210, 2008.
[52]
A. J. Reginato, J. L. Ferreiro Seoane, and C. B. Alvarez, “Arthropathy and cutaneous calcinosis in hemodialysis oxalosis,” Arthritis & Rheumatism, vol. 29, no. 11, pp. 1387–1396, 1986.
[53]
E. C. Lorenz, C. J. Michet, D. S. Milliner, and J. C. Lieske, “Update on oxalate crystal disease,” Current Rheumatology Reports, vol. 15, article 340, 2013.
[54]
B. Hoppe, “An update on primary hyperoxaluria,” Nature Reviews Nephrology, vol. 8, pp. 467–475, 2012.
[55]
S. R. Mulay, O. P. Kulkarni, K. V. Rupanagudi, A. Migliorini, M. N. Darisipudi, A. Vilaysane, et al., “Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1β secretion,” The Journal of Clinical Investigation, vol. 123, no. 1, pp. 236–246, 2013.
[56]
A. Mannoni, E. Selvi, S. Lorenzini et al., “Alkaptonuria, ochronosis, and ochronotic arthropathy,” Seminars in Arthritis and Rheumatism, vol. 33, no. 4, pp. 239–248, 2004.
[57]
L. R. Ranganath, J. C. Jarvis, and J. A. Gallagher, “Recent advances in management of alkaptonuria (invited review, best practice article),” Journal of Clinical Pathology, vol. 66, no. 5, pp. 367–373, 2013.
[58]
M. B. Perry, P. Suwannarat, G. P. Furst, W. A. Gahl, and L. H. Gerber, “Musculoskeletal findings and disability in alkaptonuria,” The Journal of Rheumatology, vol. 33, no. 11, pp. 2280–2285, 2006.
[59]
é. Toussirot and R. Aquaron, “Short-term efficacy of hyaluronic acid joint injections in a case of ochronotic arthropathy,” Journal of Clinical Rheumatology, vol. 19, no. 3, pp. 152–153, 2013.
[60]
R. V. Manoj Kumar and S. Rajasekaran, “Spontaneous tendon ruptures in alkaptonuria,” Journal of Bone and Joint Surgery B, vol. 85, no. 6, pp. 883–886, 2003.
[61]
P. Suwannarat, K. O'Brien, M. B. Perry et al., “Use of nitisinone in patients with alkaptonuria,” Metabolism: Clinical and Experimental, vol. 54, no. 6, pp. 719–728, 2005.
[62]
W. J. Introne, M. B. Perry, J. Troendle et al., “A 3-year randomized therapeutic trial of nitisinone in alkaptonuria,” Molecular Genetics and Metabolism, vol. 103, no. 4, pp. 307–314, 2011.
[63]
T. M. Cox, “Alkaptonuria: leading to the treasure in exceptions,” in JIMD Reports—Case and Research Reports, 2012/2, vol. 5 of JIMD Reports, pp. 49–57, Springer, Berlin, Germany, 2012.
[64]
A. J. Preston, C. M. Keenan, H. Sutherland, P. J. Wilson, B. Wlodarski, A. M. Taylor, et al., “Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone,” Annals of the Rheumatic Diseases, vol. 73, no. 1, pp. 284–289, 2014.
[65]
A. C. Kobak, G. Oder, ？. Kobak, M. Argin, and V. Inal, “Ochronotic arthropathy: disappearance of alkaptonuria after liver transplantation for hepatitis B-related cirrhosis,” The Journal of Clinical Rheumatology, vol. 11, no. 6, pp. 323–325, 2005.
[66]
W. J. Introne, C. Phornphutkul, I. Bernardini, K. McLaughlin, D. Fitzpatrick, and W. A. Gahl, “Exacerbation of the ochronosis of alkaptonuria due to renal insufficiency and improvement after renal transplantation,” Molecular Genetics and Metabolism, vol. 77, no. 1-2, pp. 136–142, 2002.
[67]
A. M. Taylor, A. J. Preston, N. K. Paulk, H. Sutherland, C. M. Keenan, P. J. M. Wilson, et al., “Ochronosis in a murine model of alkaptonuria is synonymous to that in the human condition,” Osteoarthritis and Cartilage, vol. 20, no. 8, pp. 880–886, 2012.
[68]
A. Spreafico, L. Millucci, L. Ghezzi, M. Geminiani, D. Braconi, L. Amato, et al., “Antioxidants inhibit SAA formation and pro-inflammatory cytokine release in a human cell model of alkaptonuria,” Rheumatology, vol. 52, no. 9, pp. 1667–1673, 2013.
[69]
M. Wiggelinkhuizen, M. E. C. Tilanus, C. W. Bollen, and R. H. J. Houwen, “Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease,” Alimentary Pharmacology and Therapeutics, vol. 29, no. 9, pp. 947–958, 2009.
[70]
J. Uetrecht, “Current trends in drug-induced autoimmunity,” Autoimmunity Reviews, vol. 4, no. 5, pp. 309–314, 2005.
[71]
H. Kodama, C. Fujisawa, and W. Bhadhprasit, “Inherited copper transport disorders: biochemical mechanisms, diagnosis, and treatment,” Current Drug Metabolism, vol. 13, no. 3, pp. 237–250, 2012.
[72]
G. J. Brewer and F. K. Askari, “Wilson's disease: clinical management and therapy,” Journal of Hepatology, vol. 42, no. 1, pp. S13–S21, 2005.
[73]
A. Nagral and K. Sathe, “Reversal of severe Wilson arthropathy by liver transplantation,” Indian Pediatrics, vol. 48, no. 5, pp. 406–407, 2011.
